Sökning: "minimal residual disease"
Visar resultat 11 - 15 av 38 avhandlingar innehållade orden minimal residual disease.
11. The use of molecular techniques for identification of genetic divergence in transplantation : with special reference to MHC genes and HLA typing
Sammanfattning : Transplantation immunology basically deals with the immune mechanisms that lead to rejection of transplanted tissues. Lymphocytes are the key mediators of graft rejection. At the time for this observation, the genetic loci responsible for histocompatibility between individuals of the same species were already identified in the mouse. LÄS MER
12. Neuroblastoma incidence, biology and outcome : with special emphasis on quantitative analysis of tyrosine hydroxylase mRNA in blood and bone marrow
Sammanfattning : Neuroblastoma, the most common malignant disease of early childhood, accounts for 6% of childhood malignancies but is responsible for 9% of paediatric cancer related deaths. The tumour originates from cells in the neural crest and has a very heterogeneous clinical course. LÄS MER
13. Ultrasensitive Molecular Monitoring of Breast Cancer and Acute Myeloid Leukemia
Sammanfattning : Cancer is the common name to a group of biologically diverse malignant neoplastic diseases. Approximately 18 million people are diagnosed with cancer annually and 8.8 million patients die from it. Tumorigenesis and progression of cancer are driven by alterations in the cancer cell genome. LÄS MER
14. The role of cannabinoid receptors, G alpha z, and B cell receptor in lymphoma pathobiology with focus on chemotaxis
Sammanfattning : Mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia (CLL) are two incurable B cell malignancies, with an overall survival of 5 to 8 years and 6 to 10 years, respectively. Therapies are available but are often very aggressive, and patients relapse due to minimal residual disease. LÄS MER
15. Molecular Monitoring of Chronic Myeloid Leukemia Treated with Imatinib Mesylate
Sammanfattning : The BCR-ABL fusion gene product is a constitutively activated tyrosine kinase, which is fundamental in the pathogenesis of chronic myeloid leukemia (CML). Imatinib mesylate (imatinib, Glivec® or Gleevec®), a small molecule inhibitor of the BCR-ABL tyrosine kinase, is now the first-line treatment for all newly diagnosed chronic phase CML patients. LÄS MER